F0285200
Flurbiprofen
European Pharmacopoeia (EP) Reference Standard
Sinonimo/i:
(±)-2-Fluoro-α-methyl-4-biphenylacetic acid, L-790,330
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Scegli un formato
50 MG
174,00 €
Scegli un formato
Cambia visualizzazione
50 MG
174,00 €
About This Item
Formula condensata:
C6H5C6H3(F)CH(CH3)CO2H
Numero CAS:
Peso molecolare:
244.26
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24
Prodotti consigliati
Grado
pharmaceutical primary standard
Famiglia di API
flurbiprofen
Produttore/marchio commerciale
EDQM
Punto di fusione
110-112 °C (lit.)
applicazioni
pharmaceutical (small molecule)
Formato
neat
Temperatura di conservazione
2-8°C
Stringa SMILE
CC(C(O)=O)c1ccc(c(F)c1)-c2ccccc2
InChI
1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
SYTBZMRGLBWNTM-UHFFFAOYSA-N
Informazioni sul gene
human ... PTGS1(5742) , PTGS2(5743)
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Descrizione generale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Applicazioni
Flurbiprofen EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Azioni biochim/fisiol
Cyclooxygenase (COX) inhibitor; non-steroidal anti-inflammatory agent with antifungal activity. The S enantiomer inhibits prostaglandin synthesis and has both anti-inflammatory and analgesic activity, while the R enantiomer does not inhibit prostaglandin synthesis and displays only analgesic activity.
Fluibiprofen is a cyclooxygenase (COX) inhibitor, which is an enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This decreases the prostaglandins which cause inflammation, pain, swelling and fever. Flurbiprofen inhibits the activity of both COX-1 and -2. The S enantiomer inhibits prostaglandin synthesis and has both anti-inflammatory and analgesic activity, while the R enantiomer does not inhibit prostaglandin synthesis and displays only analgesic activity.
Confezionamento
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Altre note
Sales restrictions may apply.
Prodotti correlati
N° Catalogo
Descrizione
Determinazione del prezzo
Avvertenze
Danger
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Acute Tox. 3 Oral
Codice della classe di stoccaggio
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Scegli una delle versioni più recenti:
Certificati d'analisi (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.
Se ti serve aiuto, non esitare a contattarci Servizio Clienti
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
A Romano et al.
Journal of internal medicine, 241(1), 81-83 (1997-01-01)
Immune-mediated reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are unusual, and true allergy to the drug flurbiprofen has never been documented. We observed a patient who developed a maculopapular rash 48 h after beginning oral therapy with this drug, and 2
Asquad Sultan et al.
The Cochrane database of systematic reviews, (3)(3), CD007358-CD007358 (2009-07-10)
Flurbiprofen is a non-selective non-steroidal anti-inflammatory drug (NSAID), related to ibuprofen and naproxen, used to treat acute and chronic painful conditions. There is no systematic review of its use in acute postoperative pain. To assess efficacy, duration of action, and
F Richy et al.
International journal of clinical practice, 61(8), 1396-1406 (2007-06-29)
The withdrawal of certain cyclooxygenase-2 selective drugs and the availability of over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs) have increased the pressure for researching and prescribing conventional NSAIDs with a favourable efficacy/tolerance ratio in inflammatory diseases, particularly rheumatoid arthritis. The aim of
R N Brogden et al.
Drugs, 18(6), 417-438 (1979-12-01)
Flurbiprofen, a phenylalkanoic acid derivative, is a non-steroidal anti-inflammatory, antipyretic, analgesic agent advocated for use in rheumatoid arthritis, degenerative joint disease, ankylosing spondylitis and allied conditions. Published data suggest that flurbiprofen 120 to 150 mg daily is comparable in effectiveness
Hugo Geerts
IDrugs : the investigational drugs journal, 10(2), 121-133 (2007-02-08)
(R)-flurbiprofen, the R-enantiomer of racemic flurbiprofen, is undergoing development by Myriad Genetics Inc, under license from Encore Pharmaceuticals Inc, for the potential treatment of Alzheimer's disease (AD). Devoid of any direct cyclooxygenase inhibition, which is associated with the more toxic
Filtri attivi
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.
